Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activated protein C: do more survive?

Literature DB >> 16228174

Activated protein C: do more survive?

Alasdair F Mackenzie¹.

Abstract

Mesh：

Substances：

Year: 2005 PMID： 16228174 DOI： 10.1007/s00134-005-2829-4

Source DB: PubMed Journal: Intensive Care Med ISSN： 0342-4642 Impact factor: 17.440

× No keyword cloud information.

11 in total

1. Assessing the use of activated protein C in the treatment of severe sepsis.

Authors: Jay P Siegel
Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245

2. Risks and benefits of activated protein C treatment for severe sepsis.

Authors: H Shaw Warren; Anthony F Suffredini; Peter Q Eichacker; Robert S Munford
Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245

3. Activated protein C for severe sepsis.

Authors: E Wesley Ely; Gordon R Bernard; Jean-Louis Vincent
Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245

4. Why are physicians so skeptical about positive randomized controlled clinical trials in critical care medicine?

Authors: Jesús Villar; Lina Pérez-Méndez; Armando Aguirre-Jaime; Robert M Kacmarek
Journal: Intensive Care Med Date: 2004-11-23 Impact factor: 17.440

5. Substantiating the concerns about recombinant human activated protein C use in sepsis.

Authors: Katherine J Deans; Peter C Minneci; Steven M Banks; Charles Natanson; Peter Q Eichacker
Journal: Crit Care Med Date: 2004-12 Impact factor: 7.598

6. Forums for expressing concerns.

Authors: Scott K Aberegg
Journal: Crit Care Med Date: 2005-06 Impact factor: 7.598

7. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Authors: Derek C Angus; Pierre-Francois Laterre; Jeff Helterbrand; E Wesley Ely; Daniel E Ball; Rekha Garg; Lisa A Weissfeld; Gordon R Bernard
Journal: Crit Care Med Date: 2004-11 Impact factor: 7.598

8. Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors: G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245

Review 9. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

Authors: R Phillip Dellinger; Jean M Carlet; Henry Masur; Herwig Gerlach; Thierry Calandra; Jonathan Cohen; Juan Gea-Banacloche; Didier Keh; John C Marshall; Margaret M Parker; Graham Ramsay; Janice L Zimmerman; Jean-Louis Vincent; Mitchell M Levy
Journal: Crit Care Med Date: 2004-03 Impact factor: 7.598

10. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

Authors: Gordon R Bernard; Benjamin D Margolis; Harvey M Shanies; E Wesley Ely; Arthur P Wheeler; Howard Levy; Kar Wong; Theressa J Wright
Journal: Chest Date: 2004-06 Impact factor: 9.410

27 in total

Activated protein C: do more survive?

1. Assessing the use of activated protein C in the treatment of severe sepsis.

2. Risks and benefits of activated protein C treatment for severe sepsis.

3. Activated protein C for severe sepsis.

4. Why are physicians so skeptical about positive randomized controlled clinical trials in critical care medicine?

5. Substantiating the concerns about recombinant human activated protein C use in sepsis.

6. Forums for expressing concerns.

7. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

8. Efficacy and safety of recombinant human activated protein C for severe sepsis.

Review 9. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

10. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

1. Evaluation of drotrecogin alpha use in a Belgian university hospital.

2. Sepsis in the ICU: who needs progress?

3. Activated protein C: do more survive?

4. Activated protein C: do more survive?

5. When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated).

6. Activated protein C in daily practice.

7. Ethical, political, and social aspects of high-technology medicine: Eos and care.

8. Drotrecogin alfa in tropical infections and refractory multi-organ failure.

9. The European Society of Intensive Care Medicine (ESICM) and the Surviving Sepsis Campaign (SSC).

10. The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia.